All In Biotech

NDA 209481 · Mylan Labs LTD

Vancomycin Hydrochloride

Vancomycin Hydrochloride · Intravenous

Last checked: Nov 20, 2026Latest source record: Jun 26, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Jul 10, 2018

Approved uses

2

Original approval plus efficacy supplements

Registered trials

501

123 Phase 3, 64 recruiting

FAERS reports

7,339

6,612 serious, 1,453 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 7, 2024.

Vancomycin Hydrochloride for Injection is a glycopeptide antibacterial indicated in adult and pediatric patients (neonates and older) for the treatment of: • Septicemia ( 1.1 ) • Infective Endocarditis ( 1.2 ) • Skin and Skin Structure Infections ( 1.3 ) • Bone Infections ( 1.4 ) • Lower Respiratory Tract Infections ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Vancomycin Hydrochloride for Injection and other antibacterial drugs, Vancomycin Hydrochloride for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.6 ) 1.1 Septicemia Vancomycin Hydrochloride for Injection is indicated in adults and pediatric patients (neonates and older) for the treatment of septicemia due to: • Susceptible isolates of methicillin-resistant Staphylococcus aureus (MRSA) and coagulase negative staphylococci. • Methicillin-susceptible staphylococci in penicillin-allergic patients, or those patients who cannot receive or who have failed to respond to other drugs, including penicillins or cephalosporins. 1.2 Infective Endocarditis Vancomycin Hydrochloride for Injection is indicated in adults and pediatric patients (neonates and older) for the treatment of infective endocarditis due to: • Susceptible isolates of MRSA. • Viridans group streptococci Streptococcus gallolyticus (previously known as Streptococcus bovis ), Enterococcus species and Corynebacterium species. For enterococcal endocarditis, use Vancomycin Hydrochloride for Injection in combination with an aminoglycoside. • Methicillin-susceptible staphylococci in penicillin-allergic patients, or those patients who cannot receive or who have failed to respond to other drugs, including penicillins or...

Mechanism: Vancomycin is an antibacterial drug [see Microbiology (12.4) ] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 26, 2024 Supplement 24 · Efficacy LetterLabel
  • Jul 10, 2018 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
6 products under this application
  • VANCOMYCIN HYDROCHLORIDE · VANCOMYCIN HYDROCHLORIDE EQ 2GM BASE/VIAL · POWDER, INTRAVENOUS · Prescription
  • VANCOMYCIN HYDROCHLORIDE · VANCOMYCIN HYDROCHLORIDE EQ 1.5GM BASE/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP
  • VANCOMYCIN HYDROCHLORIDE · VANCOMYCIN HYDROCHLORIDE EQ 750MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP
  • VANCOMYCIN HYDROCHLORIDE · VANCOMYCIN HYDROCHLORIDE EQ 1.75GM BASE/VIAL · POWDER, INTRAVENOUS · Prescription
  • VANCOMYCIN HYDROCHLORIDE · VANCOMYCIN HYDROCHLORIDE EQ 1.25GM BASE/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP
  • VANCOMYCIN HYDROCHLORIDE · VANCOMYCIN HYDROCHLORIDE EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · POWDER, INTRAVENOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Vancomycin" as an intervention, any sponsor and status, largest first.

All 501 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective850
  • acute kidney injury498
  • off label use460
  • pyrexia433
  • rash309
  • drug reaction with eosinophilia and systemic symptoms300
  • drug hypersensitivity289
  • condition aggravated267
  • pneumonia262
  • diarrhoea255
  • sepsis252
  • hypotension225

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200461
200551
200682
2007150
2008270
200999
201091
2011106
2012152
2013196
2014154
2015265
2016160
2017180
2018265
2019387
2020419
2021628
2022916
2023918
2024771
2025653
2026364

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,708 on PubMed

Sponsor: Mylan Labs LTD

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.